The Board of Directors has terminated President
and Chief Executive Officer, Douglas Bryant and appointed, on an
interim basis, Michael Iskra as Chief Executive Officer and Robert
Bujarski as President
The Board of Directors (the “Board”) of QuidelOrtho Corporation
(Nasdaq: QDEL) (the “Company” or “QuidelOrtho”) has made
significant decisions aimed to enhance operational efficiency,
drive revenue growth and deliver shareholder value.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240221157769/en/
Michael S. Iskra (Photo: Business
Wire)
After a comprehensive evaluation, the Board has terminated
Douglas Bryant, President and Chief Executive Officer of
QuidelOrtho. Mr. Bryant has also resigned from the Board, both
effective February 21, 2024.
To ensure business continuity and effective leadership, the
Board formed the Office of the Chief Executive Officer (the “Office
of the CEO”) on February 17, 2024. The Office of the CEO is led by
the Company's Executive Vice President and Chief Commercial
Officer, Michael Iskra, Executive Vice President and Chief
Operating Officer, Robert Bujarski, and Chief Financial Officer,
Joseph Busky.
In this transition, Michael Iskra has been appointed as the
Interim Chief Executive Officer, and Robert Bujarski as the Interim
President, effective February 21, 2024. Both will continue to
fulfill their current responsibilities while assuming the
additional duties of their new roles. Kenneth F. Buechler, Ph.D.,
will remain as Chairman of the Board and will provide guidance to
the Office of the CEO, supported by other Board members.
“Now is the time for a change in leadership that can accelerate
our initiatives to improve efficiencies, drive growth and increase
shareholder value,” said Kenneth F. Buechler, Ph.D., Chairman of
the Board. “All of us would like to thank Doug for his years of
dedication and wish him well in his future endeavors.”
The Board has started a comprehensive search to identify a new
Chief Executive Officer, considering both internal and external
candidates. There is no change to the Company’s financial guidance
provided on February 16, 2024. Additionally, the Company will
postpone its previously announced Investor Day until a later
date.
About Michael Iskra
Michael Iskra has over a decade of global executive leadership
experience and more than 30 years of experience in the diagnostics
and healthcare products and services industries. Michael brings
significant knowledge and expertise across strategy, sales,
marketing, operations and general management. Prior to his current
role, Michael was Executive Vice President of Commercial Excellence
and Strategy at Ortho Clinical Diagnostics Holdings plc from 2020
to 2022.
About Robert Bujarski
Robert Bujarski has two decades of enterprise experience at the
Company spanning the full spectrum of operational, commercial, and
legal functions within the diagnostics sector. Robert also brings
significant knowledge and expertise across strategy, business
development and R&D. Prior to his current role, Robert was the
Chief Operating Officer of Quidel Corporation (“Quidel”) from
September 2020 to May 2022, where he architected expansions of
Quidel’s operational scope and scale.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in
vitro diagnostics, developing and manufacturing intelligent
solutions that transform data into understanding and action for
more people in more places every day.
Offering industry-leading expertise in immunoassay and molecular
testing, clinical chemistry and transfusion medicine, bringing
fast, accurate and reliable diagnostics when and where they are
needed – from home to hospital, lab to clinic. So that patients,
clinicians and health officials can spot trends sooner, respond
quicker and chart the course ahead with accuracy and
confidence.
Building upon its many years of groundbreaking innovation,
QuidelOrtho continues to partner with customers across the
healthcare continuum and around the globe to forge a new diagnostic
frontier. One where insights and solutions know no bounds,
expertise seamlessly connects and a more informed path is
illuminated for each of us.
QuidelOrtho is advancing diagnostics to power a healthier
future. For more information, please visit www.quidelortho.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements are any statement contained herein that is
not strictly historical, including, but not limited to,
QuidelOrtho’s executive leadership transition plans, commercial,
integration, transformation and other strategic goals, financial
guidance and other future financial condition and operating
results, and future plans, objectives, strategies, expectations and
intentions. Such statements are based on the beliefs and
expectations of QuidelOrtho’s management as of today and are
subject to significant known and unknown risks and uncertainties.
Actual results or outcomes may differ significantly from those set
forth or implied in the forward-looking statements. Factors,
including those discussed under Part I, Item 1A, “Risk Factors” of
QuidelOrtho’s Annual Report on Form 10-K for the fiscal year ended
January 1, 2023 and subsequent reports filed with the Securities
and Exchange Commission, among others, could cause actual results
to differ from those set forth or implied in the forward-looking
statements. You should not rely on forward-looking statements as
predictions of future events because these statements are based on
assumptions that may not come true and are speculative by their
nature. All forward-looking statements are based on information
currently available to QuidelOrtho and speak only as of the date
hereof. QuidelOrtho undertakes no obligation to update any of the
forward-looking information or time-sensitive information included
in this press release, whether as a result of new information,
future events, changed expectations or otherwise, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240221157769/en/
Investor: Juliet Cunningham Vice President, Investor Relations
IR@QuidelOrtho.com
Media: D. Nikki Wheeler Senior Director, Corporate
Communications Media@QuidelOrtho.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Apr 2024 to May 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From May 2023 to May 2024